PerkinElmer公司借助蛋白质组学技术早期诊断癌症

 
一种针对肺、卵巢、乳房癌症进行早期检测和危险分层的新方法，将由创建新型蛋白质组学技术来完称，其原理是精确地检测和测定特异性的蛋白质片断，这些片断是人血液中可能的疾病生物学指标。

PerkinElmer公司(Boston, MA, USA)已经宣布了一项为期5年与George Mason大学(Manassas, VA, USA)合作的科研计划，以实现这种新型检测方法。PerkinElmer公司提供基因生物指标领域新技术和科学方法。来自这两个机构的科学家将共同合作设计新型临床检测平台，该平台将同时对特异性蛋白质片断的进行氨基酸鉴别和特定分子量进行鉴别，以发现生物指标。
 
Proteomics Technology May Detect Early Cancer
 
A new approach for early lung, ovarian, and breast cancer detection and risk stratification is being developed by creating a new proteomics technology to accurately detect and measure specific protein fragments in human blood that are potential biomarkers for disease.

PerkinElmer, Inc. (Boston, MA, USA), has announced a five-year research-collaboration agreement with George Mason University (Manassas, VA, USA) to work on this new approach. PerkinElmer is providing new technology and scientific expertise in genetic biomarker expression. Scientists from both organizations will work together to design new types of clinical assay latforms that use both the amino acid identification of a specific protein fragment and its specific mass to identify the biomarker.